伍梅尚扎因的抗肥胖作用:一个集成的脂管学和转录学研究
Xiao Huang1, Chunling Liao1, Bo Peng1
1Hospital of Tradition Medicine LS.SC, Leshan, Sichuan Province, China.
Frontiers in pharmacology
|November 6, 2025
概括
米山 (Wumeishanzhayin,WMSZY) 有效地减少体重增加,并改善高脂肪,高果糖饮食的小鼠的代谢障碍. 它的抗肥胖作用与通过AMPK/CPT-1通路调节脂质代谢有关.
科学领域:
- 代谢学 代谢学 代谢学
- 药理学 药理学是指药理学的学科.
- 肥胖问题研究研究
背景情况:
- 全球成人肥胖是一个日益严重的健康危机,影响超过8.9亿人.
- 植物配方Wumeishanzhayin (WMSZY) 在治疗肥胖和脂质疾病方面表现有前途.
- 需要进一步阐明WMSZY的精确治疗机制.
研究的目的:
- 为了研究WMSZY对饮食引起的肥胖症的治疗效果.
- 阐明WMSZY抗肥胖作用的基本机制.
主要方法:
- 使用UPLC-MS/MS.对WMSZY的代谢物进行分析.
- 在小鼠模型中评估WMSZY对体重,脂质和葡萄糖代谢的影响.
- 集成的脂管学,转录学,分子对接和西方斑分析,以确定关键路径和目标.
主要成果:
- 在小鼠中,WMSZY治疗减少了体重增加和改善了代谢参数.
- 脂管学数据表明,WMSZY影响胆固醇代谢,脂解和胰岛素抵抗.
- 转录组学和途径分析表明AMPK,MAPK和PPAR信号的参与.
- WMSZY激活了AMPK/CPT-1通路,并抑制了脂质代谢基因.
结论:
- 在临床前的模型中,WMSZY有效地减轻肥胖和代谢功能障碍.
- WMSZY的抗肥胖机制涉及通过AMPK/CPT-1通路调节脂质代谢.
相关概念视频
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
163
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
163
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
230
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
230


